A randomized controlled clinical trial of topical insulin-like growth factor-1 therapy for sudden deafness refractory to systemic corticosteroid treatment
Authors:
- Takayuki NakagawaTakayuki Nakagawa
- Kozo KumakawaKKKozo Kumakawa
- Shin-Ichi UsamiSUShin-Ichi Usami
- Naohito HatoNHNaohito Hato
- Keiji TabuchiKTKeiji Tabuchi
- Mariko TakahashiMTMariko Takahashi
- Keizo FujiwaraKFKeizo Fujiwara
- Akira SasakiASAkira Sasaki
- Shizuo KomuneSKShizuo Komune
- Tatsunori SakamotoTSTatsunori Sakamoto
- Harukazu HiraumiHHHarukazu Hiraumi
- Norio YamamotoNYNorio Yamamoto
Open Access
- 19 November 2014
- journal article
- research article
- Published by Springer Nature in BMC Medicine
- Vol. 12 (1) , 1-8
Abstract
To date, no therapeutic option has been established for sudden deafness refractory to systemic corticosteroids. This study aimed to examine the efficacy and safety of topical insulin-like growth factor-1 (IGF-1) therapy in comparison to intratympanic corticosteroid therapy. We randomly assigned patients with sudden deafness refractory to systemic corticosteroids to receive either gelatin hydrogels impregnated with IGF-1 in the middle ear (62 patients) or four intratympanic injections with dexamethasone (Dex; 58 patients). The primary outcome was the proportion of patients showing hearing improvement (10 decibels or greater in pure-tone average hearing thresholds) 8 weeks after treatment. The secondary outcomes included the change in pure-tone average hearing thresholds over time and the incidence of adverse events. In the IGF-1 group, 66.7% (95% confidence interval [CI], 52.9-78.6%) of the patients showed hearing improvement compared to 53.6% (95% CI, 39.7-67.0%) of the patients in the Dex group (P = 0.109). The difference in changes in pure-tone average hearing thresholds over time between the two treatments was statistically significant (P = 0.003). No serious adverse events were observed in either treatment group. Tympanic membrane perforation did not persist in any patient in the IGF-1 group, but did persist in 15.5% (95% CI, 7.3-27.4%) of the patients in the Dex group (P = 0.001). The positive effect of topical IGF-1 application on hearing levels and its favorable safety profile suggest utility for topical IGF-1 therapy in patients with sudden deafness. UMIN Clinical Trials Registry Number UMIN000004366 , October 30th, 2010.Keywords
This publication has 28 references indexed in Scilit:
- Systemic Steroid Application Caused Sudden Death of a Patient with Sudden DeafnessCase Reports in Otolaryngology, 2013
- Topical insulin-like growth factor 1 treatment using gelatin hydrogels for glucocorticoid-resistant sudden sensorineural hearing loss: a prospective clinical trialBMC Medicine, 2010
- Daily Short-Term Intratympanic Dexamethasone Treatment Alone as an Initial or Salvage Treatment for Idiopathic Sudden Sensorineural Hearing LossAudiology and Neurotology, 2010
- Sudden sensorineural hearing lossThe Lancet, 2010
- Intratympanic Steroids in Severe to Profound Sudden Sensorineural Hearing Loss as Salvage TreatmentClinical and Experimental Otorhinolaryngology, 2010
- Safety of High-Dose Corticosteroids for the Treatment of Autoimmune Inner Ear DiseaseOtology & Neurotology, 2009
- Insulin-like growth factor 1 treatment via hydrogels rescues cochlear hair cells from ischemic injuryNeuroReport, 2008
- Novel Therapy for Hearing LossOtology & Neurotology, 2007
- Thirty-year trends in sudden deafness from four nationwide epidemiological surveys in JapanActa Oto-Laryngologica, 2007
- A novel mutation in a patient with insulin-like growth factor 1 (IGF1) deficiencyJournal of Medical Genetics, 2003